Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.45Last Year’s EPS
0.45Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive performance narrative: strong double-digit revenue growth, record product and portfolio performance (notably FIRDAPSE and AGAMREE), robust profitability and cash generation, clear commercial execution improvements (patient identification, diagnostics, enrollment, and retention), and a constructive 2026 guidance range. Challenges were acknowledged—FYCOMPA's loss of exclusivity and revenue erosion, ongoing patent litigation, increasing royalties/milestones and gross-to-net pressure from IRA, and the need for additional label-supporting data for AGAMREE—all of which are being actively managed. On balance, highlights meaningfully outweigh the lowlights.Company Guidance
Record Full-Year Revenues Exceed Guidance
Total revenues for FY2025 were $589.0 million, up 19.8% year-over-year, exceeding the company's prior guidance range of $565 million to $585 million. Net product revenue for 2025 was $588.8 million, an increase of 20.3% versus 2024.
Strong FIRDAPSE Performance and Growth Outlook
FIRDAPSE net product revenue for 2025 was $358.4 million, a 17% increase year-over-year; Q4 2025 net revenues were $97.6 million, up 18.3% versus Q4 2024 and 5.9% versus Q3 2025. 2026 guidance for FIRDAPSE is $435 million to $450 million (growth of ~21.4% to 25.6%).
Exceptional AGAMREE Launch Momentum
AGAMREE delivered $117.1 million in net product revenue for 2025, up 154.3% year-over-year; Q4 2025 revenue was $35.3 million, up 67.5% versus Q4 2024. Adoption reached 100% of top DMD centers of excellence (representing ~80% of DMD patients) with 270 unique HCPs submitting enrollment forms. 2026 guidance for AGAMREE is $140 million to $150 million (growth of ~19.6% to 28.1%).
Solid FYCOMPA Cash Contribution Despite Generics
FYCOMPA generated $113.3 million in 2025 despite loss of exclusivity in May 2025. Management expects FYCOMPA revenue of $40 million to $45 million in 2026 and is discontinuing active promotion while retaining meaningful revenue contribution.
Healthy Profitability and Cash Position
Net income before taxes for 2025 was $283.5 million, a 31.1% increase versus 2024. GAAP net income was $214.3 million ($1.68 diluted EPS), up 30.8% year-over-year. Non-GAAP net income was $346.2 million ($2.72 per diluted share). Cash and cash equivalents increased to $709.2 million at year-end vs $517.6 million at 12/31/2024, driven by $208.7 million of operating cash flow.
Commercial Execution: Patient Identification and Conversion Gains
Data leads of identified LEMS patients in active diagnostic stages increased 40% in Q4 2025; the pool of identified LEMS patients exceeded 600. VGCC testing grew ~21% year-over-year and >1/3 in H2 vs H1 2025, contributing to stronger new patient enrollments. Pharmacy intervention program (launched June 2025) reduced early discontinuations by ~12%.
High AGAMREE Reimbursement and Durable Demand Signals
AGAMREE reimbursement success rates are above 85% (management notes closer to 90%). Discontinuations and cancellations meaningfully declined in H2 2025; approximately 45% of AGAMREE patients transitioned from prednisone and 42% from EMFLAZA. Median age of new enrollees dropped ~1 year (from ~12 to ~11), suggesting earlier adoption.
Robust Business Development Pipeline
BD engine assessed over 100 opportunities in 2025 (about 90% inbound), and the company expanded its search to include late-stage assets with clear regulatory paths and peak sales up to $500 million to augment organic growth.
Ongoing Clinical and Life-Cycle Programs
AGAMREE life-cycle activities include the ongoing 5-year SUMMIT study (~250 patients planned) and a Phase I study evaluating dose equivalence and immunosuppressive biomarkers (analysis expected H1 2026) to support differentiation and potential label/indication expansion.
CPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $24.88 | $23.08 | -7.23% |
Nov 05, 2025 | $21.38 | $20.99 | -1.82% |
Aug 06, 2025 | $21.79 | $19.64 | -9.89% |
May 07, 2025 | $23.46 | $22.76 | -2.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Catalyst Pharma (CPRX) report earnings?
Catalyst Pharma (CPRX) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Catalyst Pharma (CPRX) earnings time?
Catalyst Pharma (CPRX) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CPRX EPS forecast?
CPRX EPS forecast for the fiscal quarter 2026 (Q1) is 0.45.